Giant GH-secreting pituitary adenomas

Management of rare and aggressive pituitary tumors

Ilan Shimon, Raquel S. Jallad, Maria Fleseriu, Christine (Chris) Yedinak, Yona Greenman, Marcello D. Bronstein

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: Patients with acromegaly usually harbor macroadenomas measuring between 10 and 30 mm in maximal diameter. Giant (adenoma size R40 mm) GH-secreting pituitary tumors are rarely encountered and the aim of this study is to analyze different methods for managing them. Design and methods: We have identified 34 patients (15 men and 19 females) with giant adenomas among 762 subjects (4.5%) with acromegaly in our records, and characterized their clinical characteristics and response to treatment. Results: Mean age at diagnosis was 34.9G12.5 years (range, 16-67 years). Mean adenoma size was 49.4G9.4 mm (range, 40-80 mm); 30 adenomas showed cavernous sinus invasion and 32 had suprasellar extension. Twenty-nine (85%) patients had visual field defects. Mean baseline IGF1 was 3.4G1.8!ULN. All patients except one underwent pituitary surgery (one to three procedures), but none achieved hormonal remission following first surgery. Among the 28 subjects with visual disturbances, 14 recovered post-operatively and 13 improved. Treatment with somatostatin analogs was given to all patients after surgical failure. Six achieved remission, nine others were partially controlled (IGF1!1.5!ULN; 3/9 when combined with cabergoline), and 17 did not respond (two were lost). Nine patients were treated with pegvisomant, alone (nZ4) or in combination with somatostatin analogs (nZ5); five are in remission and two are partially controlled. Pasireotide-LAR achieved hormonal remission in one of the six patients. Currently, after a mean follow-up period of 8.9 years, 17 patients are in biochemical remission, eight are partially controlled, and seven are uncontrolled (two were lost to follow-up). Conclusions: Giant GH-secreting adenomas are invasive, uncontrolled by surgery, and respond poorly to medical treatment. Aggressive multimodal therapy is critical for their management, enhancing control rate and biochemical remission.

Original languageEnglish (US)
Pages (from-to)707-713
Number of pages7
JournalEuropean Journal of Endocrinology
Volume172
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Growth Hormone-Secreting Pituitary Adenoma
Pituitary Neoplasms
Adenoma
Acromegaly
Somatostatin
Allura Red AC Dye
Cavernous Sinus
Lost to Follow-Up
Therapeutics
Visual Fields

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Giant GH-secreting pituitary adenomas : Management of rare and aggressive pituitary tumors. / Shimon, Ilan; Jallad, Raquel S.; Fleseriu, Maria; Yedinak, Christine (Chris); Greenman, Yona; Bronstein, Marcello D.

In: European Journal of Endocrinology, Vol. 172, No. 6, 01.06.2015, p. 707-713.

Research output: Contribution to journalArticle

Shimon, Ilan ; Jallad, Raquel S. ; Fleseriu, Maria ; Yedinak, Christine (Chris) ; Greenman, Yona ; Bronstein, Marcello D. / Giant GH-secreting pituitary adenomas : Management of rare and aggressive pituitary tumors. In: European Journal of Endocrinology. 2015 ; Vol. 172, No. 6. pp. 707-713.
@article{633dbf36bcb54d9faf1ff668ce0bc3c6,
title = "Giant GH-secreting pituitary adenomas: Management of rare and aggressive pituitary tumors",
abstract = "Objectives: Patients with acromegaly usually harbor macroadenomas measuring between 10 and 30 mm in maximal diameter. Giant (adenoma size R40 mm) GH-secreting pituitary tumors are rarely encountered and the aim of this study is to analyze different methods for managing them. Design and methods: We have identified 34 patients (15 men and 19 females) with giant adenomas among 762 subjects (4.5{\%}) with acromegaly in our records, and characterized their clinical characteristics and response to treatment. Results: Mean age at diagnosis was 34.9G12.5 years (range, 16-67 years). Mean adenoma size was 49.4G9.4 mm (range, 40-80 mm); 30 adenomas showed cavernous sinus invasion and 32 had suprasellar extension. Twenty-nine (85{\%}) patients had visual field defects. Mean baseline IGF1 was 3.4G1.8!ULN. All patients except one underwent pituitary surgery (one to three procedures), but none achieved hormonal remission following first surgery. Among the 28 subjects with visual disturbances, 14 recovered post-operatively and 13 improved. Treatment with somatostatin analogs was given to all patients after surgical failure. Six achieved remission, nine others were partially controlled (IGF1!1.5!ULN; 3/9 when combined with cabergoline), and 17 did not respond (two were lost). Nine patients were treated with pegvisomant, alone (nZ4) or in combination with somatostatin analogs (nZ5); five are in remission and two are partially controlled. Pasireotide-LAR achieved hormonal remission in one of the six patients. Currently, after a mean follow-up period of 8.9 years, 17 patients are in biochemical remission, eight are partially controlled, and seven are uncontrolled (two were lost to follow-up). Conclusions: Giant GH-secreting adenomas are invasive, uncontrolled by surgery, and respond poorly to medical treatment. Aggressive multimodal therapy is critical for their management, enhancing control rate and biochemical remission.",
author = "Ilan Shimon and Jallad, {Raquel S.} and Maria Fleseriu and Yedinak, {Christine (Chris)} and Yona Greenman and Bronstein, {Marcello D.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1530/EJE-14-1117",
language = "English (US)",
volume = "172",
pages = "707--713",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "6",

}

TY - JOUR

T1 - Giant GH-secreting pituitary adenomas

T2 - Management of rare and aggressive pituitary tumors

AU - Shimon, Ilan

AU - Jallad, Raquel S.

AU - Fleseriu, Maria

AU - Yedinak, Christine (Chris)

AU - Greenman, Yona

AU - Bronstein, Marcello D.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objectives: Patients with acromegaly usually harbor macroadenomas measuring between 10 and 30 mm in maximal diameter. Giant (adenoma size R40 mm) GH-secreting pituitary tumors are rarely encountered and the aim of this study is to analyze different methods for managing them. Design and methods: We have identified 34 patients (15 men and 19 females) with giant adenomas among 762 subjects (4.5%) with acromegaly in our records, and characterized their clinical characteristics and response to treatment. Results: Mean age at diagnosis was 34.9G12.5 years (range, 16-67 years). Mean adenoma size was 49.4G9.4 mm (range, 40-80 mm); 30 adenomas showed cavernous sinus invasion and 32 had suprasellar extension. Twenty-nine (85%) patients had visual field defects. Mean baseline IGF1 was 3.4G1.8!ULN. All patients except one underwent pituitary surgery (one to three procedures), but none achieved hormonal remission following first surgery. Among the 28 subjects with visual disturbances, 14 recovered post-operatively and 13 improved. Treatment with somatostatin analogs was given to all patients after surgical failure. Six achieved remission, nine others were partially controlled (IGF1!1.5!ULN; 3/9 when combined with cabergoline), and 17 did not respond (two were lost). Nine patients were treated with pegvisomant, alone (nZ4) or in combination with somatostatin analogs (nZ5); five are in remission and two are partially controlled. Pasireotide-LAR achieved hormonal remission in one of the six patients. Currently, after a mean follow-up period of 8.9 years, 17 patients are in biochemical remission, eight are partially controlled, and seven are uncontrolled (two were lost to follow-up). Conclusions: Giant GH-secreting adenomas are invasive, uncontrolled by surgery, and respond poorly to medical treatment. Aggressive multimodal therapy is critical for their management, enhancing control rate and biochemical remission.

AB - Objectives: Patients with acromegaly usually harbor macroadenomas measuring between 10 and 30 mm in maximal diameter. Giant (adenoma size R40 mm) GH-secreting pituitary tumors are rarely encountered and the aim of this study is to analyze different methods for managing them. Design and methods: We have identified 34 patients (15 men and 19 females) with giant adenomas among 762 subjects (4.5%) with acromegaly in our records, and characterized their clinical characteristics and response to treatment. Results: Mean age at diagnosis was 34.9G12.5 years (range, 16-67 years). Mean adenoma size was 49.4G9.4 mm (range, 40-80 mm); 30 adenomas showed cavernous sinus invasion and 32 had suprasellar extension. Twenty-nine (85%) patients had visual field defects. Mean baseline IGF1 was 3.4G1.8!ULN. All patients except one underwent pituitary surgery (one to three procedures), but none achieved hormonal remission following first surgery. Among the 28 subjects with visual disturbances, 14 recovered post-operatively and 13 improved. Treatment with somatostatin analogs was given to all patients after surgical failure. Six achieved remission, nine others were partially controlled (IGF1!1.5!ULN; 3/9 when combined with cabergoline), and 17 did not respond (two were lost). Nine patients were treated with pegvisomant, alone (nZ4) or in combination with somatostatin analogs (nZ5); five are in remission and two are partially controlled. Pasireotide-LAR achieved hormonal remission in one of the six patients. Currently, after a mean follow-up period of 8.9 years, 17 patients are in biochemical remission, eight are partially controlled, and seven are uncontrolled (two were lost to follow-up). Conclusions: Giant GH-secreting adenomas are invasive, uncontrolled by surgery, and respond poorly to medical treatment. Aggressive multimodal therapy is critical for their management, enhancing control rate and biochemical remission.

UR - http://www.scopus.com/inward/record.url?scp=84930582397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930582397&partnerID=8YFLogxK

U2 - 10.1530/EJE-14-1117

DO - 10.1530/EJE-14-1117

M3 - Article

VL - 172

SP - 707

EP - 713

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 6

ER -